Alnylam, Nastech Take Different IP Approaches To Pandemic Flu RNAi Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.
You may also be interested in...
Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward
Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.
Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward
Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.
Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate
Tacere Therapeutics has entered into a strategic alliance with Tokyo-based Oncolys BioPharma to develop its lead RNA interference-based candidate for treatment of hepatitis C, the companies announced June 21